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Salmonella enterica serovars Typhimurium and Enteritidis are the predominant causes of 
invasive non-typhoidal Salmonella (iNTS) disease. Considering the co-endemicity of S. 
Typhimurium and S. Enteritidis, a bivalent vaccine formulation against both pathogens 
is necessary for protection against iNTS disease, thus investigation of glycoconjugate 
combination is required. In the present work, we investigated the immune responses 
induced by S. Typhimurium and S. Enteritidis monovalent and bivalent glycoconjugate 
vaccines adjuvanted with aluminum hydroxide (alum) only or in combination with 
cytosine-phosphorothioate-guanine oligodeoxynucleotide (CpG). Humoral and cellular, 
systemic and local, immune responses were characterized in two different mouse 
strains. All conjugate vaccines elicited high levels of serum IgG against the respective 
O-antigens (OAg) with bactericidal activity. The bivalent conjugate vaccine induced 
systemic production of antibodies against both S. Typhimurium and S. Enteritidis OAg. 
The presence of alum or alum +  CpG adjuvants in vaccine formulations significantly 
increased the serum antigen-specific antibody production. The alum +  CpG bivalent 
vaccine formulation triggered the highest systemic anti-OAg antibodies and also a sig-
nificant increase of anti-OAg IgG in intestinal washes and fecal samples, with a positive 
correlation with serum levels. These data demonstrate the ability of monovalent and 
bivalent conjugate vaccines against S. Typhimurium and S. Enteritidis to induce systemic 
and local immune responses in different mouse strains, and highlight the suitability of a 
bivalent glycoconjugate formulation, especially when adjuvanted with alum + CpG, as a 
promising candidate vaccine against iNTS disease.
Keywords: glycoconjugate vaccines, Salmonella Typhimurium, Salmonella enteritidis, O-antigen, immunogenicity, 
bivalent vaccine, adjuvants
inTrODUcTiOn
Salmonella enterica serovars Typhimurium (S. Typhimurium) and Enteritidis (S. Enteritidis) are the 
predominant causes of invasive non-typhoidal Salmonella (iNTS) disease, a bloodstream infection 
with high prevalence in sub-Saharan Africa, especially among young children and HIV-infected 
individuals (1, 2). The case fatality rate of iNTS disease is around 20%, and the effectiveness of 








1418 O:4,5-CRM197 2.2 12.4 0.40
2189 O:4,5-CRM197 1.2 <20 0.49
618 O:9-CRM197 2.3 17.9 0.47
Unconjugated CRM197 – – 0.72
Unconjugated 1418 O:4,5 – – 0.56 and 0.67
Unconjugated 2189 O:4,5 – – 0.57 and 0.68
Unconjugated 618 O:9 – – 0.62
aOAgs to CRM197 ratios were calculated based on OAg concentration by phenol sulfuric 
assay and protein concentration by micro BCA. Amount of free OAg was calculated 
following conjugate precipitation with deoxycholate. Kd (distribution coefficient) values 
were calculated by HPLC-SEC analysis on TSK gel 6000-5000 PW columns (flow rate 
0.5 ml/min; eluent 100 mM NaH2PO4, 100 mM NaCl, 5% CH3CN pH 7.2), using the 
following equation: Kd = (Te − T0)/(Tt − T0), where Te = elution time of the analyte, 
T0 = elution time of the biggest fragment of λ-DNA, and Tt = elution time of NaN3.
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antibiotic treatment is hampered by a growing frequency of 
multidrug resistance (2, 3). No vaccine against iNTS disease is 
currently available and, in the ongoing efforts to identify protec-
tive antigens, lipopolysaccharide (LPS) has been recognized as 
an important target of the protective immune response (4–6). 
LPS is composed of lipid A (endotoxin), attached to the 3-deoxy-
D-manno-octulosonic acid (KDO) terminus of the conserved 
core region, which is linked to a variable O-antigen (OAg) chain 
containing serogroup-specific repeating units (7). The OAg of S. 
Typhimurium and S. Enteritidis contain a common trisaccharide 
backbone and a serogroup-specific side chain, providing O:4,5 
and O:9 specificities for S. Typhimurium and S. Enteritidis, 
respectively. Although the OAg chain and core sugar alone consti-
tute a poor immunogen, OAg conjugated to a carrier protein can 
elicit protective immunity against lethal challenge, with anti-OAg 
antibodies effective in adoptive transfer experiments (8–11). In 
previous work, we have shown that OAg-CRM197 glycoconjugates 
induce functional antigen-specific serum antibody in mice (6, 
12) and that conjugation parameters, such as polysaccharide 
structural fine specificities, polysaccharide/carrier protein ratio, 
and conjugation chemistry, can all influence the immunogenicity 
of such glycoconjugates (13–15).
Considering the frequent co-endemicity of S. Typhimurium 
and S. Enteritidis serovars, a bivalent vaccine formulation against 
both pathogens would be of critical importance. Glycoconjugate 
combinations represent a promising approach to vaccine devel-
opment. The development of immune responses by a glycoconju-
gate vaccine can be influenced by adjuvants that can enhance the 
immunogenicity of the vaccine antigens, improve vaccine efficacy 
in newborns, elderly, and immunocompromised individuals, and 
facilitate the uptake of antigens by the mucosa (16). Adjuvants 
can achieve qualitative modulation of the immune response and 
promote types of immunity not effectively generated by the non-
adjuvanted antigens (17). Here, aluminum hydroxide (alum) and 
unmethylated cytosine-phosphorothioate-guanine oligodeoxy-
nucleotide (CpG ODN)  adjuvants were tested. Alum induces a 
Th2-biased immune response with predominantly B-cell-related 
humoral immunity (18). It has been approved by the Food and 
Drug Administration for formulation with human vaccines and 
has been in use for the past 60 years, indicating an excellent safety 
profile (19, 20). CpG ODN are potent stimulators of both innate 
and adaptive immune responses through the Toll-like receptor 
9 (TLR9) (21, 22). CpG ODN stimulate cellular and humoral 
responses, strongly promote Th1 responses (23, 24), and have 
been licensed for cancer immunotherapy (25). More recently, the 
combination of antigens with more than one adjuvant, known as 
the adjuvant system approach, has been used to develop vaccines 
generating improved immune responses (26, 27).
In the present work, we investigated the immune responses 
induced by subcutaneous immunization with S. Typhimurium and 
S. Enteritidis glycoconjugate vaccines by characterizing humoral 
and cellular, systemic and local, immune responses in two differ-
ent mouse strains, CB6F1 and C57BL/6. We tested monovalent 
(O:4,5-CRM197 or O:9-CRM197) and bivalent (O:4,5-CRM197 and 
O:9-CRM197) vaccine formulations, adjuvanted with alum only 
or in combination with CpG ODN. Antigen-specific antibodies 
in serum, intestinal washes and feces, serum bactericidal activity 
(SBA), and cytokine production in restimulated splenocytes were 
analyzed. The results obtained show the suitability of a bivalent 
adjuvanted glycoconjugate formulation as a promising candidate 
vaccine against iNTS disease.
MaTerials anD MeThODs
antigens
Origin of Bacterial Strains
The clinical isolate S. Typhimurium D23580 was obtained 
from the Malawi-Liverpool-Wellcome Trust Clinical Research 
Programme, Blantyre, Malawi. D23580 is a representative 
Malawian isolate belonging to ST313 sequence type isolated from 
a case of iNTS disease (28–30). S. Enteritidis CMCC4314 (corre-
sponding to ATCC4931) was obtained from the Novartis Master 
Culture Collection. S. Typhimurium 2189 and 1418 (14) were 
obtained from University of Calgary, Canada (Salmonella Genetic 
Stock Centre): 2189 belonged to the Salmonella reference collec-
tion A (SARA) (31) and 1418 belonged to the LT2-collection (32). 
S. Enteritidis 618 (14) was obtained from Quotient Bioresearch 
Limited, UK and was isolated by the European Antimicrobial 
Susceptibility Surveillance in Animals, coordinated by the 
European Animal Health Study Centre, Brussels (CEESA) (33).
Synthesis and Characterization of Conjugate 
Vaccines
OAg were purified from S. Typhimurium 2189 and 1418 and from 
S. Enteritidis 618 strains and fully characterized as previously 
reported (14, 34, 35). Those strains were selected as potential 
sources of OAg for OAg-conjugate vaccines (14). For conjugation 
to CRM197 (received by Novartis Vaccines), OAg was derivatized 
with adipic acid dihydrazide (ADH) by reductive amination of 
the KDO terminal sugar and linked to the amino groups on the 
protein after attachment of a second linker, adipic acid bis(N-
hydroxysuccinimide) (SIDEA), to ADH. Conditions used for 
conjugation and assays for characterization of OAg-CRM197 con-
jugates were as previously described (13–15). The main charac-
teristics of the conjugates tested in this study are listed in Table 1. 
TaBle 2 | Vaccine formulations used for immunogenicity studies in cB6F1 and c57Bl/6 mice.
Mice straina group  
(number of mice per group)
Vaccine formulation
immunogenb adjuvant Dose of O-antigen  
(μg/mouse)
Dose of crM197  
(μg/mouse)
CB6F1 1 (8) O:4,5-CRM197 – 8 6.8
2 (8) O:9-CRM197 – 8 3.5
3 (8) O:4,5-CRM197 + O:9-CRM197 (bivalent) – 8 + 8 10.3 (6.8 + 3.5)
4 (8) O:4,5-CRM197 + O:9-CRM197 (bivalent) Alum 8 + 8 10.3 (6.8 + 3.5)
5 (8) O:4,5-CRM197 + O:9-CRM197 (bivalent) Alum + CpG 8 + 8 10.3 (6.8 + 3.5)
6 (6) O:4,5 – 8 –
7 (6) O:9 – 8 –
8 (6) CRM197 – – 10.3
9 (6) Saline – – –
C57BL/6 1 (8) O:4,5-CRM197 Alum 8 6.8
2 (8) O:4,5-CRM197 Alum + CpG 8 6.8
3 (8) O:9-CRM197 Alum 8 3.5
4 (8) O:9-CRM197 Alum + CpG 8 3.5
5 (8) O:4,5-CRM197 + O:9-CRM197 (bivalent) Alum 8 + 8 10.3 (6.8 + 3.5)
6 (8) O:4,5-CRM197 + O:9-CRM197 (bivalent) Alum + CpG 8 + 8 10.3 (6.8 + 3.5)
7 (8) – Alum + CpG – –
aCB6F1 mice were used to study long-term humoral and cellular, local and systemic, immune responses and functional activity; C57BL/6 mice were used to study humoral systemic 
immune responses and functional activity.
bO:4,5: O-antigen from S. Typhimurium (2189 for CB6F1 and 1418 for C57BL/6 mice); O:9: O-antigen from S. Enteritidis; CRM197: non-toxic mutant of diphtheria toxin.
Alum, alhydrogel; CpG, cytosine-phosphorothioate-guanine oligodeoxynucleotide.
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All conjugates had no free protein detectable (by HPLC-SEC) 
(36) and less than 20% free saccharide (following precipitation of 
the conjugate with deoxycholate) (37). HPLC-SEC profiles of the 
conjugates indicated a clear shift at higher molecular weight with 
respect to unconjugated protein and OAg, as shown by lower Kd 
(distribution coefficient) values reported in Table 1.
antigens Formulation
NTS glycoconjugates were diluted in saline or formulated with 
either alum only (Alhydrogel, Brenntag Biosector, Denmark) 
(2  mg/ml final concentration, measured as alum content) or 
with both alum (2 mg/ml) and CpG ODN 1826 (hereafter CpG; 
Invitrogen, 5′-TCCATGACGTTCCTGACGTT-3′; 0.1  mg/ml 
final concentration) in saline, as detailed in Table 2. Each formu-
lation was stirred for 1 h at room temperature, and the tubes were 
mixed again before injecting into mice.
Analysis by HPLC-SEC revealed that, at the concentrations 
tested in the study, less than 2% CpG was attached to alum and in 
both formulations much less than 10% conjugates remained free 
in the supernatant.
animal studies
Groups of 6 week-old female CB6F1 mice and 5 week-old female 
C57BL/6 were purchased from Charles River Laboratories 
(Lecco, Italy). CB6F1 stain is a chimeric strain of mice (BALB/c  ×  
C57BL/6), used to evaluate both humoral and cellular immune 
responses; C57BL/6 is a Th1-polarized inbred strain. Animals 
were maintained under specific pathogen-free conditions in the 
animal facilities at the Laboratory of Molecular Microbiology 
and Biotechnologies (LA.M.M.B.) at University of Siena or at 
Novartis Animal Facility in Siena. All animal protocols were 
approved by the local animal ethics committees (authorization 
N. 4/2011, July 20, 2011 by “Comitato Etico Locale dell’Azienda 
Ospedaliera Universitaria Senese” for CB6F1 mice and approval 
N. AEC201018 for C57BL/6 mice) and by the Italian Minister 
of Health in accordance with Italian law (Decreto Legislativo 
26/2014).
immunizations and sample collection
Two immunogenicity studies were conducted as described in 
Figure 1, Figure S1A in Supplementary Material, and Table 2.
Groups of eight or six CB6F1 mice were immunized at weeks 0 
and 4. Half of the animals for each group were sacrificed at week 
11; the other half received a further immunization at week 9 and 
were sacrificed at week 15. Groups of eight C57BL/6 mice were 
immunized at weeks 0 and 4 and sacrificed at week 7. In both 
studies, each immunization was administered subcutaneously in 
a volume of 200 μl/mouse.
Blood samples were taken from the temporal plexus (subman-
dibular vein) on weeks 0, 2, 4, 6, 9, 11, 13, and 15 (for CB6F1 study) 
and on weeks 0, 2, 4, 6, and 7 (for C57BL/6 study), incubated for 
30 min at 37°C and centrifuged at 1,200 × g at 4°C for 15 min. 
Serum samples were stored at −80°C.
Fecal samples were collected from CB6F1 mice on weeks 0, 
6, 9, 11, 13, and 15; feces evacuated from individual mice were 
weighed and carefully dissolved in 100 mg/ml of PBS–1% BSA 
(Sigma-Aldrich), centrifuged at 15,000 ×  g at 4°C for 10  min, 
and protease inhibitor cocktails (Sigma-Aldrich) were added to 
supernatants before storage at −80°C.
Intestinal washes were performed at the time points of sac-
rifice (weeks 11 and 15) of CB6F1 mice; the small intestine was 
removed and washed with 1  ml of PBS-1% BSA (BSA, Sigma-
Aldrich) three times. Samples were centrifuged at 10,000 × g at 
4°C for 10 min, and protease inhibitor cocktails (Sigma-Aldrich) 
were added to supernatants before storage at −80°C. Erythrocyte 
contamination was estimated by comparing erythrocyte number 
FigUre 1 | experimental design for immunogenicity studies with cB6F1 mice.
4
Fiorino et al. Glycoconjugate Vaccines for Non-Typhoidal Salmonella
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 168
in intestinal washes with that of blood and were found to be too 
low to account for the observed intestinal antibody response.
Spleens were collected from each CB6F1 mouse at sacrifice, 
mashed through nylon screens (Sefar Italia, Italy), and washed 
in complete medium [cRPMI, RPMI 1640 (Gibco, USA) sup-
plemented with 10% (v/v) fetal bovine serum (Gibco), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Sigma-Aldrich)].
enzyme-linked immunosorbent assay 
(elisa)
Serum Antibodies
Serum anti-O:4,5 (from 2189 strain for study with CB6F1 mice and 
from 1418 strain for study with C57BL/6 mice), anti-O:9 (from 
strain 618), and anti-CRM197 IgG, IgG1, IgG2a, IgG2b, IgG2c, 
IgG3, IgA, and IgM were determined by ELISA (14). Maxisorp 
microtiter plates (Nunc, Denmark) were coated with O:4,5 
(5 µg/ml), O:9 (15 µg/ml), or CRM197 (2 µg/ml) overnight at 4°C in 
a carbonate buffer, pH 9.4, in a volume of 100 µl/well. Coating was 
removed and plates were blocked with 200 µl/well of PBS–0.05% 
Tween 20–5% fat-free milk (AppliChem, Germany) for 1  h at 
room temperature. Plates were washed with PBS–0.05% Tween 
20 (Sigma-Aldrich), and serum samples were added and titrated 
in twofold dilutions in duplicate or triplicate in PBS–0.05% Tween 
20–0.1% BSA (diluent buffer) in 100 µl/well. After incubation for 
2 h at room temperature, plates were washed, incubated for 1 h at 
room temperature with the alkaline phosphatase-conjugated goat 
anti-mouse IgG, IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgA, and IgM 
(all diluted 1:1,000 and from Southern Biotechnology, USA) in 
100 µl/well, and developed by adding 1 mg/ml of alkaline phos-
phatase substrate (Sigma-Aldrich) in 100 µl/well. The end point 
reading was performed using Versamax ELISA reader (Molecular 
Devices, Italy) or Synergy HT reader (Biotek Instruments, USA). 
Antibody titers were expressed as the reciprocal of the dilution 
of sample reporting the double OD value compared to the 
background.
Mucosal Antibodies
Anti-O:4,5 and anti-O:9 IgG and IgA in intestinal washes and in 
fecal samples were determined by ELISA, as previously described 
(38). As the concentration of IgG and IgA in intestinal washes is 
variable, the amount of anti-O:4,5 and anti-O:9 IgG or IgA was 
normalized to the total IgG or IgA concentration in each sample. 
Total IgG and IgA were determined on flat bottom Maxisorp 
microtiter plates coated with anti-mouse IgG or IgA (1  µg/ml; 
Southern Biotechnology), while anti-O:4,5 and anti-O:9 IgG or 
IgA were assayed on the same plates as described above. Samples 
were tested in twofold dilutions in duplicate in plates incubated 
overnight at 4°C. The concentration of total, anti-O:4,5, and anti-
O:9 IgG or IgA was calculated against a standard curve of mouse 
myeloma standard IgG or IgA (Southern Biotechnology) deter-
mined on the same plate. The end point reading was performed 
using Versamax ELISA reader (Molecular Devices, Italy). Results 
were expressed as microgram of anti-O:4,5 and anti-O:9 IgG or 
IgA per milligram of total IgG or IgA.
sBa assay
Equal volumes of mouse sera collected from CB6F1 mice at 
week 11 and from C57BL/6 mice at week 7, belonging to the 
same immunization group (Table  2), were pooled together for 
SBA experiments, as previously described (15). S. Typhimurium 
D23580 and S. Enteritidis CMCC4314 strains were used as target 
strains to perform SBA reactions as previously reported (14, 15). 
They were grown in Luria Bertani (LB) medium to log-phase (OD: 
0.2), diluted 1:30,000 in PBS to approximately 3 ×  103 colony-
forming units (CFU)/ml and distributed into sterile polystyrene 
U bottom 96-well microtiter plates (12.5 µl/well). Serum samples, 
serially diluted twofold or threefold (starting from 1:100 dilu-
tion), were added to each well (final volume 50 µl, ~620 CFU/ml). 
Sera were heat-inactivated and baby rabbit complement 
(Cedarlane CL3441) was used at 50% of the final volume. Each 
sample and control was tested in triplicate on three different days. 
One hundred microliters reaction mixtures from each well were 
spotted on LB-agar plates at time 0 (T0) to assess initial CFU 
and at 3 h (T180) after incubation at 37°C. LB-agar plates were 
incubated overnight at 37°C and the resulting CFU were counted 
the following day. Bactericidal activity was determined as serum 
dilutions necessary to obtain 50% CFU reduction at T180 com-
pared with T0. Serum titers equal to 1 were designated when no 
bactericidal activity was detected.
T elisPOT
IL-2 and IFN-γ production was analyzed in splenocytes, as 
previously described (39), following two immunizations (week 
11). The number of spot-forming units (SFU) was evaluated using 
the Mouse IL-2 and Mouse IFN-γ ELISPOT ready-SET-Go kits, 
according to the manufacturer’s protocol (Affymetrix eBiosci-
ence). Ninety-six-well multiscreen filtration plates (Millipore, 
USA) were coated overnight at 4°C with capture IL-2 or IFN-γ 
FigUre 2 | S. Typhimurium O-antigen-specific serum igg, serum 
bactericidal activity (sBa), and igg subclasses in cB6F1 mice. Mice 
were subcutaneously immunized at weeks 0, 4, and 9 with different vaccine 
formulations, as reported in Table 2. (a) Time course of anti-O:4,5 IgG 
assessed by ELISA in individual serum samples on weeks 0, 2, 4, 6, 9, 11, 
13, and 15 following the first immunization. Arrows represent the timing of 
immunizations. Values are reported as geometric mean titers (GMT) ± SEM. 
(B) SBA on pooled sera collected at week 11 and tested against S. 
Typhimurium D23580 isolates. Bactericidal activity was determined as  
serum dilutions necessary to obtain 50% CFU reduction at T180 compared  
with T0. Bars represent the mean SBA titers ± SEM of triplicate samples.  
(c) Anti-O:4,5 IgG1, IgG2a, IgG2b, and IgG3 assessed by ELISA in individual 
serum samples collected at week 11. Values are reported as GMT ± SEM. 
Statistical analysis was performed using one-way ANOVA and Tukey’s post 
test for multiple comparisons. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
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antibody solution. Free binding sites were blocked with cRPMI. 
Pooled splenocytes for each group (three to four mice per group) 
were seeded in triplicate in a final volume of 200 µl/well of cRPMI 
at a density of 1 × 106 cells/well, as determined in a pilot study 
using different cell densities in a range suggested by the manufac-
turer’s protocol. Cells were stimulated with 10 µg/ml of CRM197 
(T-dependent antigen) or of the respective OAg (T-independent 
antigen) and incubated for 40 h at 37°C with 5% CO2. A positive 
and a negative control [splenocytes in  vitro restimulated with 
10  µg/ml concanavalin A (Sigma-Aldrich) or unstimulated, 
respectively] were included for each group of immunization. 
After washing steps, plates were incubated with biotinylated IL-2 
or IFN-γ detection antibody at room temperature for 2 h. Plates 
were added with avidin-HRP solution for 45 min and developed 
with AEC Substrate Solution (Sigma-Aldrich) at room tem-
perature. Spots were counted using a computer-assisted ELISPOT 
image analyzer (Cellular Technologies Limited, Germany). Data 
were expressed as SFU per million of cells.
statistical analysis
Sera, fecal samples, and intestinal washes for ELISA were tested 
individually, and the amount of antibodies were expressed as 
geometric mean titers (GMT) or concentration ± standard error 
of the mean (SEM). Sera for SBA were tested as a pool for each 
group of immunization and data were expressed as SBA titers 
± SEM. Statistical differences between antibody production 
among groups were assessed using one-way analysis of variance 
(ANOVA) and Tukey’s post test for multiple comparisons. Two-
tailed Student’s t-test was used for analyzing antibody amounts at 
two different time points or for evaluating statistical differences 
among two independent groups. Statistical analysis of titer values 
was performed on log-transformed data. The correlation among 
the antibody concentration between sera and fecal samples 
or intestinal washes in each animal was performed calculating 
Pearson’s correlation coefficient, r. Statistical significance was 
defined as P ≤ 0.05. Graphpad 4.0 software was used for analysis.
resUlTs
serum antibody responses in Mice 
immunized with adjuvanted and 
Unadjuvanted conjugate Vaccines
Serum antibody response induced by monovalent S. Typhim-
urium (O:4,5-CRM197) and S. Enteritidis (O:9-CRM197) conjugate 
vaccines or by bivalent (O:4,5-CRM197 + O:9-CRM197) conjugate 
formulations, unadjuvanted or adjuvanted with alum only, or 
with alum plus CpG, was analyzed in CB6F1 mice immunized 
with the different vaccine formulations (Table 2) according to the 
experimental design reported in Figure 1.
All monovalent and bivalent, adjuvanted or unadjuvanted, 
conjugate vaccines elicited levels of anti-O:4,5 IgG serum titers 
significantly higher (P < 0.001) than the control groups uncon-
jugated OAg (O:4,5 or O:9 polysaccharides), saline and CRM197 
(Figure 2A; Table S1 in Supplementary Material). The bivalent 
formulation adjuvanted with alum + CpG triggered the highest 
anti-O:4,5 IgG response, which was significantly higher compared 
to bivalent vaccine with alum only or unadjuvanted formula-
tions (P < 0.05; Figure 2A; Tables S1 and S2 in Supplementary 
Material). SBA was observed for both monovalent O:4,5-CRM197 
and bivalent vaccines (both adjuvanted and unadjuvanted) 
(Figure  2B). On the contrary, no functional activity against S. 
Typhimurium D23580 was observed in mice immunized with 
Enteritidis O:9-conjugate (Figure  2B), although antibodies 
cross-reactive with O:4,5 were detected by ELISA (Figure 2A). 
The analysis of anti-O:4,5 serum IgG subclasses showed a strong 
predominance of IgG1 in all groups of mice vaccinated with con-
jugate vaccines suggesting a Th2 polarization (Figure 2C; Table 
S5 in Supplementary Material). The bivalent vaccine adjuvanted 
with alum only elicited a stronger Th2 response compared to 
the same vaccine adjuvanted with alum + CpG, with an IgG1/
IgG2a ratio fivefold higher (P < 0.01; Table S6 in Supplementary 
Material).
FigUre 3 | S. enteritidis O-antigen-specific serum igg, serum 
bactericidal activity (sBa), and igg subclasses in cB6F1 mice. Mice 
were subcutaneously immunized at weeks 0, 4, and 9 with different vaccine 
formulations, as reported in Table 2. (a) Time course of anti-O:9 IgG 
assessed by ELISA in individual serum samples on weeks 0, 2, 4, 6, 9, 11, 
13, and 15 following the first immunization. Arrows represent the timing of 
immunizations. Values are reported as GMT ± SEM. (B) SBA on pooled sera 
collected at week 11 and tested against S. Enteritidis CMCC4314 isolates. 
Bactericidal activity was determined as serum dilutions necessary to obtain 
50% CFU reduction at T180 compared with T0. Bars represent the mean 
SBA titers ± SEM of triplicate samples. (c) Anti-O:9 IgG1, IgG2a, IgG2b, and 
IgG3 assessed by ELISA on individual serum samples collected at week 11. 
Values are reported as GMT ± SEM. Statistical analysis was performed using 
one-way ANOVA and Tukey’s post test for multiple comparisons. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001.
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The analysis of O:9 IgG response showed significant levels 
of serum antibodies in mice immunized with the Enteritidis 
monovalent or bivalent vaccines and, as expected, not in 
mice immunized with S. Typhimurium monovalent vaccine 
(Figure 3A; P <  0.05 compared to control groups; Table S3 in 
Supplementary Material). As for anti-O:4,5, the bivalent vaccine 
including alum + CpG induced anti-O:9 IgG serum titers that 
were significantly higher compared to formulation including 
alum only or without adjuvants (P <  0.05; Figure  3A; Tables 
S3 and S4 in Supplementary Material). Functional activity 
against S. Enteritidis CMCC4314 was observed for monovalent 
O:9-CRM197 and all bivalent vaccines (Figure 3B). Significantly 
higher levels of anti-O:9 IgG1 subclass were detected compared to 
IgG2a, IgG2b, and IgG3 in mice immunized with O:9 monovalent 
and bivalent conjugate formulations, confirming a Th2 polariza-
tion (P < 0.05; Figure 3C; Table S7 in Supplementary Material). 
The bivalent vaccine adjuvanted with alum only elicited a 
stronger Th2 response compared to the same vaccine adjuvanted 
with alum +  CpG, with an IgG1/IgG2a ratio ninefold higher 
(P < 0.001; Table S8 in Supplementary Material). No statistical 
differences were observed in the ratio between IgG1 and other 
IgG subclasses (data not shown).
Data observed in CB6F1 mice were confirmed in C57BL/6 
mice immunized according to the experimental design reported in 
Figure S1A in Supplementary Material and Table 2. As expected, 
in this mouse strain, known to be less skewed toward a humoral 
response, antigen-specific antibodies’ titers were lower compared 
to those of CB6F1 mice. A significant increase in anti-O:4,5 or anti-
O:9 IgG was observed in animals immunized with all adjuvanted 
glycoconjugate formulations with respect to the control group 
injected with the adjuvant only (P <  0.001; Figures S1B,E and 
Tables S9 and S11 in Supplementary Material). The highest levels 
of anti-O:4,5 or anti-O:9 IgG were induced after immunization 
with the vaccines adjuvanted with both alum and CpG compared 
to the same vaccines adjuvanted with alum only (P < 0.05; Tables 
S10 and S12 in Supplementary Material). SBA was observed in 
mice immunized with bivalent and homologous monovalent 
vaccine formulations (Figures S1C,F in Supplementary Material). 
No SBA against S. Typhimurium was observed for monovalent 
Enteritidis conjugate (Figure S1C in Supplementary Material), 
although antibodies cross-reactive with O:4,5 were detected by 
ELISA (Figure S1B in Supplementary Material), confirming data 
previously observed for CB6F1 mice (Figure 2B).
Similar to what observed with CB6F1 mice, the analysis of 
IgG subclasses showed that the presence of CpG as adjuvant 
in vaccine formulations enhanced the anti-O:4,5 and anti-O:9 
IgG2b and IgG2c response compared to monovalent or bivalent 
vaccines adjuvanted with alum only, skewing the response toward 
a weaker Th2 polarization (Figures S1D,G and Tables S13–S16 in 
Supplementary Material).
All conjugate vaccines induced anti-CRM197-specific serum 
IgG significantly higher than unconjugated CRM197 in CB6F1 
mice (P < 0.001; Figure S2 in Supplementary Material). The alum 
plus CpG adjuvanted bivalent formulation elicited a significantly 
higher response compared to the unadjuvanted bivalent vaccine 
(Figure S1 in Supplementary Material).
Serum anti-O:4,5 IgM were detected in groups of CB6F1 
mice immunized with bivalent or Typhimurium monovalent 
conjugate, but not with Enteritidis monovalent conjugate, and 
titers were up to three times higher compared to control groups 
after the second immunization. No differences were observed for 
anti-O:9 IgM elicited among all conjugate formulations (data not 
shown).
Low levels of serum anti-O:4,5 and O:9 IgA were observed in 
all glycoconjugate formulations tested after two or three immu-
nizations, with no differences compared to control groups (data 
not shown).
local antibody responses in cB6F1 Mice 
immunized with adjuvanted and 
Unadjuvanted conjugate Vaccines
The local anti-O:4,5 and O:9 antibody response was analyzed in 
the intestinal tract of CB6F1 mice immunized with monovalent 
FigUre 4 | S. Typhimurium and enteritidis O-antigen-specific igg in intestinal washes and feces. CB6F1 mice were subcutaneously immunized with 
different vaccine formulations (as reported in Table 2) at weeks 0, 4, and 9 and sacrificed after two doses (week 11, blue histograms) or three doses (week 15, 
green histograms). Anti-O:4,5 and anti-O:9 IgG were assessed by ELISA in individual intestinal washes (a,D) and fecal samples (B,e) collected after two or three 
immunizations. (c,F). Time course of anti-O:4,5 and anti-O:9 IgG assessed on fecal samples collected on weeks 0, 6, 9, 11, 13, and 15 from mice immunized with 
adjuvanted or unadjuvanted bivalent vaccines. All values are reported as mean concentration ± SEM. Statistical analysis were performed using one-way ANOVA and 
Tukey’s post test for multiple comparisons, or two-tailed Student’s t-test to compare differences of the same vaccine at different time points. *P ≤ 0.05, **P ≤ 0.01, 
and ***P ≤ 0.001.
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(O:4,5-CRM197 or O:9-CRM197) and bivalent (O:4,5-CRM197 and 
O:9-CRM197) conjugate formulations, unadjuvanted or adju-
vanted with alum only or alum + CpG (Table 2), according to 
the experimental design reported in Figure 1. Antigen-specific 
IgG and IgA concentrations, normalized to total IgG and IgA, 
were evaluated in intestinal washes and in fecal samples.
Significantly higher levels of anti-O:4,5 and anti-O:9 IgG were 
detected in intestinal washes of mice immunized (two or three 
times) with the bivalent vaccine adjuvanted with alum + CpG, 
in comparison to unconjugated polysaccharides (P < 0.01) and 
O:4,5 monovalent conjugate vaccines (P < 0.05; Figures 4A,D).
In fecal samples, significant anti-O:9 fecal IgG was induced by 
the bivalent vaccine adjuvanted with alum + CpG with respect 
to bivalent vaccine adjuvanted with alum only or unadjuvanted 
(P < 0.05) and to monovalent conjugate or unconjugate (P < 0.01; 
Figure  4E) vaccines. Significant levels of anti-O:4,5 fecal IgG 
were also detected in mice immunized with the bivalent vaccine 
adjuvanted with alum +  CpG, in comparison to unconjugated 
polysaccharides (P < 0.01) and O:4,5 monovalent conjugate vac-
cines (P < 0.05; Figure 4B).
The time course analysis showed that the increase in fecal 
anti-O:4,5 and anti-O:9 IgG, induced by the bivalent vaccine 
adjuvanted with alum +  CpG, started at week 9 with a peak 
4 weeks after the third immunization (week 13), and levels were 
maintained also at week 15 (Figures 4C,F).
Interestingly, a positive correlation of both anti-O:4,5 and 
anti-O:9 IgG levels was found between intestinal washes and fecal 
samples for each mouse with r ≥ 0.93 (P ≤ 0.05) in mice immu-
nized with the bivalent vaccine adjuvanted with alum +  CpG 
(data not shown). In the same group, positive correlation was also 
observed between sera and both intestinal washes and fecal sam-
ples with r ≥ 0.92 (P ≤ 0.05) and r ≥ 0.72 (P ≤ 0.05), respectively 
(data not shown).
Very low levels of both anti-O:4,5 and anti-O:9 IgA, normal-
ized to total IgA, were observed in intestinal washes and fecal 
samples of mice immunized (two or three times) with all conju-
gate formulations, and no differences were detected compared to 
control group (data not shown).
cellular immune response in cB6F1 Mice 
immunized with adjuvanted and 
Unadjuvanted conjugate Vaccines
IL-2 production was investigated in splenocytes of CB6F1 mice 
after in  vitro restimulation with the carrier protein CRM197. 
Bivalent conjugate vaccines were more efficient in stimulating 
a T-cell response, in terms of IL-2 SFU, compared to control 
groups vaccinated with unconjugated O:4,5 and O:9 (P < 0.05; 
Figure  5). Moreover, the presence of adjuvants in the bivalent 
vaccine formulations induced a higher number of IL-2 producing 
FigUre 5 | il-2 splenocyte response. CB6F1 mice were subcutaneously 
immunized at weeks 0 and 4 with different vaccine formulations, as reported 
in Table 2. Splenocytes were collected at week 11 following the first 
immunization, and IL-2 production was evaluated by ELISPOT assay. The 
number of antigen-specific spot-forming units (SFU) of CRM197 in vitro 
stimulated minus the respective unstimulated samples is shown. Each bar 
represents the mean number of SFU/106 cells of pooled splenocytes. 
Statistical analysis was performed using one-way ANOVA and Tukey’s post 
test for multiple comparisons. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 versus 
both unconjugated polysaccharides.
8
Fiorino et al. Glycoconjugate Vaccines for Non-Typhoidal Salmonella
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 168
cells (P < 0.01, Figure 5). IL-2 SFU similar to the control groups 
or saline (≤ 2 SFU/106 cells, data not shown) were detected in 
all glycoconjugate immunized groups after in  vitro restimula-
tion with OAg (data not shown). No increase in IFN-γ SFU was 
detected in all groups, independently of the antigen used for the 
in vitro stimulation (data not shown). As expected, immunization 
of mice with each unconjugated OAg did not induce appreciable 
production of cytokines, being a T-cell independent antigen.
DiscUssiOn
In this work, we have evaluated the immunogenicity of monova-
lent and bivalent glycoconjugates as promising candidate vaccines 
against S. Typhimurium and S. Enteritidis. A bivalent conjugate 
vaccine against both S. Typhimurium and S. Enteritidis would 
be a promising tool to overcome the frequent co-endemicity of 
these serogroups. The conjugation of a polysaccharide antigen to 
a carrier protein constitutes a strategy of proven effectiveness to 
enhance the immunogenicity of polysaccharide alone, by induc-
ing T helper cell-mediated antibody responses. Additionally, the 
use of adjuvants can achieve qualitative alteration of the immune 
response, improve vaccine efficacy, and shape the immune 
response (16, 17).
In previous work, we undertook an extensive strain selection 
process, which resulted in the identification of S. Typhimurium 
and S. Enteritidis isolates that could be used as a safe and effective 
source for glycoconjugate vaccines against iNTS disease in Africa 
(14). Those conjugates were able to induce high antibody levels 
with high breadth of serovar-specific strain coverage, when tested 
as monovalent unadjuvanted vaccines. Here, we employed those 
selected glycoconjugates to further investigate the humoral and 
cellular, systemic and local, immune responses elicited in bivalent 
formulations, adjuvanted or not.
In the present study, testing monovalent and bivalent glycocon-
jugates against S. Typhimurium and S. Enteritidis in two mouse 
strains, we have shown: (i) increased magnitude and persistence 
of anti-O:4,5 and anti-O:9 IgG in mice vaccinated with bivalent or 
homologous monovalent conjugate vaccines compared to uncon-
jugated OAg; (ii) no interference in IgG response when both S. 
Typhimurium and S. Enteritidis conjugates were administered 
together as a bivalent formulation; (iii) higher IgG levels in mice 
immunized with bivalent vaccine adjuvanted with alum only, or 
with alum + CpG, compared to unadjuvanted vaccine; (iv) SBA 
with bivalent and homologous monovalent vaccine formulations; 
(v) prevalence of specific IgG1 subclass for monovalent and 
bivalent conjugate vaccines; (vi) higher ratio of IgG1/IgG2a for 
vaccine adjuvanted with alum compared to alum + CpG (likely 
reflecting the influence of these adjuvants on the Th response); 
(vii) presence of IgG in intestinal washes and fecal samples 
induced by alum  +  CpG-adjuvanted bivalent vaccines; (viii) 
positive correlation of IgG levels between sera, intestinal washes, 
and fecal samples; and (ix) higher IL-2 production in splenocytes 
of mice vaccinated with adjuvanted bivalent conjugate vaccines.
Both S. Typhimurium and S. Enteritidis monovalent or bivalent 
vaccine formulations were highly immunogenic in both CB6F1 
and C57BL/6 mouse strains. The S. Typhimurium conjugate elic-
ited an anti-O:4,5-specific IgG response and no cross-reaction with 
S. Enteritidis O:9 antigen. In contrast, the S. Enteritidis conjugate 
surprisingly was able to trigger an IgG response that cross-reacted 
with S. Typhimurium OAg, reaching serum titers as high as those 
induced by the equivalent S. Typhimurium conjugate. The reason 
for such cross-reactivity is under investigation, but is most likely 
due to antibody directed against common OAg epitopes, such as 
O:1 and O:12, or against the common core region. These more 
internal antigens may become accessible to antibody binding 
when coated on an ELISA plate, while remaining less accessible 
in live bacteria, thus explaining the lack of functional bactericidal 
activity of antibody directed against them. In earlier studies, it 
was found that monoclonal IgG3 antibodies directed against O:4 
and O:12 showed a marked difference in protective activity, with 
the anti-O:12 monoclonal 2,500-fold less protective than the O:4 
monoclonal (40).
Regarding IgG subclass switch, it is commonly accepted that 
Th1/Th2 polarization is dependent on different factors, such as 
the genetic predisposition of mouse strain, the vaccine formula-
tion used, and the route of immunization. Adjuvants play a 
critical role in shaping the immune response to vaccine formula-
tions. No study has been conducted so far using adjuvanted OAg 
conjugates with either monovalent or bivalent iNTS conjugate 
formulations. Alum (aluminum salts) is known to induce a Th2 
response in mice (41) but a mixture of Th2 and Th1 in humans 
(42), while CpG ODN activates antigen-presenting cells and B 
cells by binding to Toll-like receptor 9 (TLR9). The interaction 
of TLR9 with CpG motifs initiates a cascade of events resulting 
in the secretion of Th1-type cytokines, and antibody response is 
most efficient when the CpG is chemically linked (43) or associ-
ated with the antigen and bound to alum (44), for a synergic 
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effect (45). A Th1/Th2 response can influence the IgG subclasses 
that are produced, which in turn can influence the bactericidal 
activity of the sera from immunized mice (12). Evaluating 
whether formulation with Th1/Th2 adjuvants can improve the 
anti-OAg response and the bactericidal activity can potentially 
guide optimal conjugate formulation.
In this work, both alum and CpG adjuvants administered with 
conjugate formulations modulated the skewing of the immune 
response, confirming what has been previously reported in rela-
tion to IgG subclasses switching (46). More specifically, our data 
demonstrate the ability of glycoconjugate vaccines to drive a Th2 
immune response, as indicated by the dominant IgG1 response, 
particularly with the alum-adjuvanted vaccines. The adjuvant 
CpG, combined with alum, was able to reduce the Th2/Th1 ratio 
in both CB6F1 and C57BL/6 mice. The presence of CpG in the 
vaccine formulation enhances the IgG2a, IgG2b, and IgG2c titers 
compared to alum only, in monovalent and bivalent conjugate 
vaccines.
In terms of CRM197-specific serum IgG, all conjugates were 
able to generate much higher responses than the group immu-
nized with unconjugated CRM197. Indeed, mice injected twice 
with unconjugated CRM197 were not able to produce high levels 
of CRM197-specific IgG. Similar data were previously obtained 
using Vi-CRM197, a Salmonella Typhi conjugate vaccine (47), but 
are actually discordant from what has been published by Pecetta 
et  al. (48), who found higher anti-CRM197 responses induced 
by the protein alone compared to the protein conjugated to 
meningococcal polysaccharide. In this specific case, the authors 
postulated that structural modifications of the carrier protein 
during the glycoconjugation induced conformational changes 
with consequent alteration of the antibody recognition and 
modulation of immunogenicity. However, they also found lower 
intrinsic immunogenicity of CRM197 compared to diphtheria 
toxoid, which could be related to a different stability of the two 
proteins. In our case, we postulate that the conjugation of OAg 
chains to CRM197 leads to a “stabilization” of the protein, enhanc-
ing its immunogenicity.
Here, we have shown that the bivalent conjugate vaccine adju-
vanted with alum +  CpG triggered the highest anti-O:4,5 and 
anti-O:9 IgG in intestinal tract, with statistically significant levels 
in intestinal washes and fecal samples compared to the respective 
monovalent conjugate and unconjugate formulations. A positive 
correlation was observed between antigen-specific IgG detected 
in intestinal washes collected when mice were sacrificed, and 
fecal samples collected at the same time point, suggesting that 
feces constitute valid alternative samples to intestinal washes to 
follow the intestinal immune response in vivo. Good correlation 
was also observed for IgG levels between serum and intestinal 
washes and between serum and fecal samples, confirming what 
was previously found with Vi-CRM197 vaccine (47). These find-
ings support the concept of passive diffusion of IgG from blood to 
intestine and confirm the potential of parenteral immunization in 
inducing antibody response in local compartments, as reported 
in different works using other conjugate vaccines (47), soluble 
immunogens (49), or purified flagellin (50). The higher systemic 
and local antibody response obtained for bivalent adjuvanted 
conjugate vaccines reflected the higher T cell response observed 
in terms of IL-2 SFU in the spleen. These data are consistent with 
the critical involvement of the pure T-dependent antigen CRM197 
for the in vitro cytokine response, as confirmed by the absence 
of IL-2 production after restimulation with each unconjugated 
polysaccharide.
Taken together, these data demonstrate the ability of mono-
valent and bivalent conjugate vaccines against S. Typhimurium 
and S. Enteritidis to induce systemic and local immune responses, 
and highlight the suitability of the bivalent glycoconjugate for-
mulation, especially adjuvanted with alum + CpG, as a promising 
candidate vaccine against iNTS disease.
aUThOr cOnTriBUTiOns
FF, SR, FMi, CM, and DM conceived and designed the experi-
ments. FF, FMi, LL, RA, and FMa performed the experiments. 
FF, SR, FMi, RA, FMa, CM, and DM analyzed the data. FF, SR, 
FMi, and DM wrote the paper. SR, FMi, LL, RA, and CM provided 
reagents. FF, SR, FMi, LL, RA, FMa, CM, and DM revised the 
manuscript, read, and approved the final manuscript.
acKnOWleDgMenTs
The authors thank Allan Saul and Annalisa Ciabattini for critical 
reading of the manuscript.
FUnDing
This study was sponsored by Novartis Vaccine for Global Health, 
now acquired by the GSK group of companies.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.00168/full#supplementary-material.
FigUre s1 | S. Typhimurium and S. enteritidis O-antigen-specific serum 
igg, serum bactericidal activity (sBa), and igg subclasses in c57Bl/6 
mice. Mice were subcutaneously immunized at weeks 0 and 4 with different 
vaccine formulations, as reported in Table 2. (a) Experimental design for 
immunogenicity study. (B,e) Time course of anti-O:4,5 (B) and anti-O:9 (e) IgG 
assessed by enzyme-linked immunosorbent assay (ELISA) in individual serum 
samples on weeks 0, 2, 4, 6, and 7 following the first immunization. Arrows 
represent the timing of immunizations. (c,F) SBA on pooled sera collected at 
week 7 and tested against S. Typhimurium D23580 (c) and S. Enteritidis 
CMCC4314 (F) isolates. Bactericidal activity was determined as serum dilutions 
necessary to obtain 50% percent colony-forming unit reduction at T180 
compared with T0. Bars represent the mean SBA titers ± SEM of triplicate 
samples. (D,g) Anti-O:4,5 (D) and anti-O:9 (g) IgG1, IgG2b, IgG2c, and IgG3 
were assessed by ELISA on individual serum samples collected at week 7. All 
values are reported as geometric mean titers (GMT) ± SEM. Statistical analysis 
was performed using one-way analysis of variance and Tukey’s post test for 
multiple comparisons. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
FigUre s2 | crM197-specific serum igg response. CB6F1 mice were 
subcutaneously immunized at weeks 0 and 4 with different vaccine formulations, 
as reported in Table 2. CRM197-specific IgG was assessed by ELISA in individual 
serum samples collected at week 11. Values are reported as geometric mean 
titers (GMT) ± SEM. One-way analysis of variance and Tukey’s post test for 
multiple comparisons were used for comparing antibody response between 
different groups. ***P ≤ 0.001 versus control groups.
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